DHI vs OptimizeRx
DHX and OPRX side by side, both in miscellaneous business services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DHX and OPRX compare
DHI is the larger company, worth 1.5 times as much as OptimizeRx ($184M against $125M).
On earnings, OptimizeRx is cheaper: it trades at 27.7× trailing earnings, against 141× for DHI.
OptimizeRx grew revenue faster over the last twelve months (−5.8% versus −7.3% for DHI).
OptimizeRx keeps more of each dollar of sales as profit, with a net margin of 4.7% compared with 0.97% at DHI.
OptimizeRx scores higher on the StockData Score (10 against 4 for DHI), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DHX | OPRX |
|---|---|---|
| Size and price | ||
| Market cap | $184M | $125M |
| Share price | $4.23 | $6.64 |
| Change, 1 year | 127% | −57.1% |
| Change, 5 years | −22.2% | −90.3% |
| Beta (5Y) | 1.05 | 1.56 |
| Employees | 270 | 104 |
| StockData Score | ||
| Total score | 4 | 10 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 0 | 2 (better) |
| Performance score | 1 | 2 (better) |
| Health score | 2 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 141× | 27.7× (better) |
| P/S | 1.5× | 1.3× (better) |
| P/B | 2.0× | 1.0× (better) |
| EV/EBITDA | 35.0× | 7.9× (better) |
| P/FCF | 9.1× | 6.8× (better) |
| FCF yield | 11.0% | 14.7% (better) |
| Fair value | $2.07 | $10.13 |
| Margin of safety | −104% | 34.5% (better) |
| Growth | ||
| Revenue growth (TTM) | −7.3% | −5.8% (better) |
| Revenue growth, 5Y average | 2.8% | 20.4% (better) |
| Profitability | ||
| Gross margin | 83.8% (better) | 73.2% |
| Operating margin | 4.9% | 11.1% (better) |
| Net margin | 0.97% | 4.7% (better) |
| FCF margin | 16.2% | 18.6% (better) |
| Return on equity | 1.2% | 3.7% (better) |
| Return on invested capital | 2.4% | 5.8% (better) |
| Financial health | ||
| Debt / equity | 0.34 | 0.15 (better) |
| Net debt / EBITDA | 4.67 (better) | −0.33 |
| Interest coverage | 2.5× (better) | 2.3× |
| Current ratio | 0.44 | 5.58 (better) |
| Altman Z-score | 1.91 | 2.72 (better) |
| Piotroski F-score | 3 | 8 (better) |
| Dividends and buybacks | ||
| Buyback yield | 7.1% | – |
| Shareholder yield | 7.1% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 70.5% | 59.6% |
| Held by insiders | 18.6% | 19.4% |
| Insider net buying, 12 months | −$265K | −$18.8K (better) |
| Short interest, % of float | 0.88% | 7.8% |
Go deeper
- DHX stock overview
- DHX income statement
- DHX valuation and score
- OPRX stock overview
- OPRX income statement
- OPRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.